Pearls

Treating psychosis in pregnant women: A measured approach

Author and Disclosure Information

 

References

The peak age of onset of schizophrenia coincides with the peak childbearing age of 25 to 35 years.1 So it would not be unusual for your patient with schizophrenia to tell you she is trying to get pregnant, or thinks she might be pregnant. In these situations, you must carefully weigh the risks to the mother (eg, relapse, complications) and to the fetus (eg, possible miscarriage, teratogenesis) when deciding whether to continue or change her treatment regimen. When faced with making these decisions, keep the following factors in mind.

1. Most importantly: Do not make knee-jerk changes. Do not suddenly stop medications. Proceed in a thoughtful and measured way.

2. Discuss the risks with your patient. There is no such thing as a risk-free decision. There are potential risks from untreated psychosis as well as from medications. Mothers with untreated psychosis have an increased risk of suicide and violence, as well as poor self-care. Schizophrenia may be associated with an increased risk of poor birth outcomes, including preterm delivery, low birthweight, and neonatal complications.2 Avoid making absolute statements about specific medications during pregnancy; there needs to be an individualized risk-benefit discussion for each patient, and for each medication.

3. Involve the patient’s partner and family in treatment planning if possible. The patient’s family can be important in promoting mental health during pregnancy and the postpartum. Educating the family as well as the patient regarding medications and the risks of untreated mental illness can go a long way toward compliance.

4. Do not rely on what pregnancy category a medication was. There are multiple dimensions to evaluate when considering the use of an antipsychotic agent during pregnancy. Does it increase the risk of miscarriage? Malformations? Preterm birth? Perinatal toxicity? Behavioral teratogenesis (neurodevelopmental sequelae)? Looking for a simple summary or single letter grade minimizes the understanding of the specific outcome of concern in the specific mother. Instead, look at the Pregnancy section under Use in Specific Populations on the medication’s package insert (prescribing information), consult a web site such as MotherToBaby (mothertobaby.org/healthcare-professionals/), and/or search for the latest research on PubMed.

5. Collaborate with the patient’s obstetrician or family medicine physician. Make sure that you are on the same page regarding treating the patient’s psychosis. Other clinicians often will agree with your treatment plan because they understand the risks of untreated psychosis compared with other risks the patient is facing. However, if you don’t communicate with your patient’s other health care professionals, she might receive mixed messages.

6. As for medication choice, pregnancy is the most important time to conduct a careful medication history to inform your choice of medication. Was Medication X ineffective, or did the patient not pick it up from the pharmacy? Did she really have a trial of 3 months, or did she only take it for a week before she decided to stop?

Continue to: Determine which medication has worked for the patient in the past

Pages

Recommended Reading

Ketamine for acute catatonia: A case report
MDedge Psychiatry
Efficacy and safety of high-dose antipsychotic therapy
MDedge Psychiatry
FDA okays new drug option for schizophrenia, bipolar I disorder
MDedge Psychiatry
Emotional support animals help lick symptoms of depression, anxiety in serious mental illness
MDedge Psychiatry
Once-weekly oral antipsychotic for schizophrenia on the horizon
MDedge Psychiatry
Schizophrenia meds a key contributor to cognitive impairment
MDedge Psychiatry
Cortical thinning in adolescence ‘definitively’ tied to subsequent psychosis
MDedge Psychiatry
How a community-based program for SMI pivoted during the pandemic
MDedge Psychiatry
Emerging drugs for schizophrenia targeting negative symptoms
MDedge Psychiatry
Long-acting injectable antipsychotics deserve first-line consideration
MDedge Psychiatry